Possibility of measuring serum taurine level as an early marker in the prognosis of thyroid disorders, especially thyroid cancer

Magdoline M. I. Mousa 1, *, Ibraheem M. A. EL Agouza 1, Ayman A. Amin 2, Hafez F. H. 3 and Mervat M. Omran 4, 5

1 Department of Zoology, Faculty of Science, Cairo University, Egypt.
2 Department of Surgery, Faculty of Medicine, National cancer institute, Cairo University, Egypt.
3 Department of Medical biochemistry, Faculty of Medicine, National cancer institute, Cairo University, Egypt.
4 Department of Cancer biology, Faculty of Medicine, National cancer institute, Cairo University, Egypt.
5 Biological science division, Faculty of Medicine, University of Chicago, Illinois, USA.
 
Research Article
GSC Biological and Pharmaceutical Sciences, 2024, 27(01), 268–276.
Article DOI: 10.30574/gscbps.2024.27.1.0135
Publication history: 
Received on 11 March 2024; revised on 22 April 2024; accepted on 24 April 2024
 
Abstract: 
People's awareness of thyroid diseases has gradually grown along with the gradual rise in thyroid cancer incidence. Thyroid dysfunction imposes a significant psychological burden on those who are diagnosed, as it affects most physiological processes. At the moment, ultrasonography and fine needle aspiration cytology are the primary methods used to diagnose thyroid cancer. There are still certain thyroid nodules that cannot be accurately and adequately classified as benign or malignant prior to surgery. Consequentially, we suggested using a more sensitive biomarker to diagnose thyroid cancer. Taurine is measured in the plasma of 60 patients from the National Cancer Institute and 10 healthy volunteers. After a full clinical examination, 20 patients were diagnosed with goitres, 20 with benign tumours, and 20 with malignant tumours. The results showed non-significant (P > 0.05) changes in the levels of TSH in all patients except in the goitre group (P < 0.001). Serum taurine levels exhibited values that significantly differed from normal (P< 0.05) for goitre and benign tumours and (P < 0.001) for malignant tumours. In conclusion, it would appear that taurine can be used as a sensitive biomarker in the early prognosis of thyroid cancer.
 
Keywords: 
Thyroid Cancer; Goiter; Taurine; FSH; Oxidative Stress
 
Full text article in PDF: 
Share this